Interval chemotherapy for colorectal cancer patients undergoing multimodal two-stage hepatectomy for bilobar liver metastases

Experimental intervention: Three cycles of antitumor systemic treatment during hypertrophy induction prior to 2nd stage hepatectomy according to physician’s choice: • Permissible agents: 5-fluorouracil/ folinic acid, oxaliplatin, irinotecan • Monochemotherapy or combination of chemotherapeutic agents (doublet chemotherapy: FOLFOX, FOLFIRI, triplet chemotherapy: FOLFOXIRI) • Dose reductions of chemotherapy allowed according to investigator’s discretion • Addition of an anti-EGFR antibody in RAS wildtype patients is allowed Control intervention: no systemic treatment during hypertrophy induction prior to intended 2nd stage hepatectomy

Status: In Vorbereitung

Klinische Settings

Beteiligte

Identifier

Kontakt